Evidence map›Paper›PMID 41406153›Full record

ArticlePLoS pathogens2025

Cardiovirus-Mediated PKR inhibition results from nucleocytoplasmic trafficking disruption.

Romane Milcamps, Belén Lizcano-Perret, Fanny Wavreil, Marielle Lebrun, Chiara Aloise, Didier Vertommen, Gaëtan Herinckx, Frank J M van Kuppeveld, Catherine Sadzot, Thomas Michiels

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Romane MilcampsUniversité catholique de Louvain, de Duve Institute, Brussels, Belgium.
Belén Lizcano-PerretUniversité catholique de Louvain, de Duve Institute, Brussels, Belgium.
Fanny WavreilUniversité catholique de Louvain, de Duve Institute, Brussels, Belgium.
Marielle LebrunULiege, GIGA-Immunobiology, laboratory of Virology and Immunology, Liège, Belgium.
Chiara AloiseUtrecht University, Section of Virology, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht, the Netherlands.
Didier VertommenMASSPROT platform, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Gaëtan HerinckxMASSPROT platform, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Frank J M van KuppeveldUtrecht University, Section of Virology, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht, the Netherlands.
Catherine SadzotULiege, GIGA-Immunobiology, laboratory of Virology and Immunology, Liège, Belgium.
Thomas MichielsUniversité catholique de Louvain, de Duve Institute, Brussels, Belgium.ORCID 0000-0001-9615-8053

Funding

Duve InstituteFonds de la recherche scientifique-FNRS
6 · The paper itself

Abstract

Eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2), known as PKR, is a key antiviral kinase activated by double-stranded RNA (dsRNA) typically produced during viral replication. Upon activation, PKR phosphorylates eIF2α, leading to the inhibition of translation and viral replication. However, many viruses have evolved mechanisms to counteract PKR activity. In Cardioviruses, the leader protein (L), a short peptide cleaved from the N-terminus of the viral polyprotein, not only inhibits PKR but also blocks interferon production and disrupts nucleocytoplasmic trafficking (NCT). L disrupts NCT by recruiting host RSK kinases to the nuclear pore complex (NPC), where RSK phosphorylates FG-nucleoporins, thereby impairing NCT. L mutations that affect NCT disruption also impact PKR inhibition, suggesting a mechanistic link between NCT and PKR activity. Recombinant TMEV and EMCV viruses designed to disrupt NCT through different mechanisms exhibited some extent of PKR inhibition, supporting the link between NCT disruption and PKR inhibition. Immunostaining and live-cell imaging revealed that, during mitosis and after L-induced NCT disruption, a fraction of PKR maps to the nucleoli, where PKR remains inactive despite its recruitment by dsRNA-like structures. This suggests that nucleolar sequestration contributes to PKR inhibition. Additionally, L-mediated NCT disruption leads to the release of nuclear RNA-binding proteins (nRBPs) into the cytosol, which may bind or modify viral dsRNA, further preventing PKR activation. Collectively, these results highlight nucleocytoplasmic trafficking as a critical regulatory mechanism governing PKR activation. Thus, beyond the specific action of cardiovirus L protein, our study reveals that interference with host nucleocytoplasmic transport can significantly impact the subcellular localization and functional regulation of immune effectors such as PKR.

Indexed as

CardiovirusCardiovirus InfectionsCell NucleuseIF-2 KinaseActive Transport, Cell NucleusAnimalsHumansVirus ReplicationEIF2AK2 protein, humaneIF-2 Kinase

Identifiers

PMID41406153
PMCPMC12747429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.